Canopy Growth Q4 revenue +10% to $71.2M; net loss narrows 21%; targets positive EBITDA in FY2027

Canopy Growth Corp

Consolidated Q4 net revenue $71.2M (+10% YoY); full-year $284.6M (+6%).
Canada medical cannabis Q4 revenue $25.3M (+27%); international markets Q4 $8.6M (+68%).
Net loss from continuing operations narrowed 21% in Q4; adjusted EBITDA loss improved to $6.3M from $9.2M.
Ended FY2026 with $131.3M net cash vs. $172.6M net debt at end of FY2025; free cash outflow improved to $69.1M.
Guidance: expects positive adjusted EBITDA in FY2027; integration of MTL Cannabis ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Canopy Growth Corp reported the fiscal fourth quarter ended March 31, 2026 results: revenue $71.2M.

Period: the fiscal fourth quarter ended March 31, 2026
Revenue: $71.2M
Result: reported results

Exact text from the filing

Consolidated net revenue of $71.2M in Q4 FY2026 increased 10% over the same period in the prior year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Canopy Growth Corp reported the fiscal year ended March 31, 2026 results: revenue $284.6M.

Period: the fiscal year ended March 31, 2026
Revenue: $284.6M
Result: reported results

Exact text from the filing

Consolidated net revenue in FY2026 was $284.6M, an increase of 6% compared to the fiscal year ended March 31, 2025 (" FY2025").

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Canopy Growth Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-270277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.